NOTE: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-21-224-L01-P), you are NOT eligible to also receive CE credit for this home-study activity.
This activity is one of a three-part series. View all three to get the most from this webinar series:
|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
The COVID-19 pandemic continues to pose a critical health crisis in many countries. Pneumonia remains a common manifestation of COVID-19, and pneumonia with respiratory failure is a significant cause of COVID-19 deaths. Bacterial coinfections are common in patients with respiratory viral infections and are associated with increased serious morbidity and mortality.
This series will increase the knowledge, competence, and performance of pharmacists in the recognition and management of bacterial pneumonia in patients with COVID-19. These activities seek to raise awareness of the significant impact of bacterial pneumonia in patients with COVID-19, the role of rapid diagnostics in these disease states, key antimicrobial stewardship strategies, and to equip pharmacists with the knowledge necessary to design a therapeutic plan for a patient with bacterial pneumonia and COVID-19.
The target audience for this activity includes pharmacists, including community pharmacists, ambulatory care, and infectious diseases pharmacists, pharmacy directors, and other pharmacy professionals responsible for the treatment and management of bacterial pneumonia in patients with COVID-19. At the completion of this activity, the participant will be able to:
- Recognize the significant impact of bacterial pneumonia in patients with COVID-19.
- Identify the role of rapid diagnostics in limiting adverse outcomes of bacterial pneumonia in patients with COVID-19.
- Describe antimicrobial stewardship strategies and tools in the armamentarium that can be utilized to aid in the management of bacterial pneumonia in patients with COVID-19.
- Given a patient case, design a therapeutic plan for a patient with bacterial pneumonia and COVID-19.
Grace Mortrude, PharmD
Infectious Diseases Clinical Pharmacy Specialist
Clement J Zablocki VA Medical Center
Eric Wenzler, PharmD, BCPS, BCIDP, AAHIVP
Department of Pharmacy Practice, College of Pharmacy
University of Illinois at Chicago
Infectious Diseases Clinical Pharmacist
Department of Pharmacy Practice
University of Illinois Hospital and Health Sciences System
Angelina Davis, PharmD, MS, BCPS, BCIDP
DASON Liaison Clinical Pharmacist
Duke Antimicrobial Stewardship Outreach Network (DASON)
Velliyur Viswesh, PharmD, BCIDP, BCCCP
Associate Professor, College of Pharmacy
Roseman University of Health Sciences
Infectious Disease and Critical Care Pharmacist
Department of Pharmacy
Valley Hospital Medical Center
Las Vegas, NV
Jeffrey C. Pearson, PharmD, BCIDP
Clinical Pharmacy Specialist, Infectious Diseases
Brigham and Women's Hospital
Release Date: September 24, 2021
Expiration Date: September 24, 2022
This activity is jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-224-H01-P has been assigned to this home study, knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Davis has received consulting fees from Merck. Dr. Mortrude does not have any relevant financial and/or commercial relationships to disclose. Dr. Pearson has received consulting fees from Gilead Sciences, Inc. and Shionogi, Inc. Dr. Viswesh has received consulting fees from Shionogi, Inc., and has received fees for non-CME/CE services from the American College of Clinical Pharmacy and the Society of Infectious Diseases Pharmacists. Dr. Wenzler has received consulting fees from Allergan Plc, GenMark Diagnostics, Melinta Therapeutics, LLC, Merck Sharp & Dohme Corp., and Shionogi, Inc.; he has also received fees for non-CME/CE services from Allergan Plc, Astellas Pharma, and Melinta Therapeutics, LLC.
This activity is supported by educational grants from bioMérieux, Melinta Therapeutics, LLC, and Merck Sharp & Dohme Corp.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.